Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 3/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 3/20 | 0.37 |
| ▸ | FNTB | P49356 | 3/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338505 | 1.00 | EPHX2 (0.43) | EPHX2CA2CA4NOD1GNPAT | |
| SCHEMBL2576084 | 0.99 | EPHX2 (0.43) | EPHX2CA2CA4NOD1GNPAT | |
| SCHEMBL2576082 | 0.99 | EPHX2 (0.43) | EPHX2CA2CA4NOD1GNPAT | |
| SCHEMBL3276934 | 0.97 | EPHX2 (0.43) | EPHX2CA2CA4NOD1GNPAT | |
| SCHEMBL3276924 | 0.97 | EPHX2 (0.43) | EPHX2CA2CA4NOD1GNPAT | |
| SCHEMBL2577659 | 0.88 | FOLH1 (0.44) | NOD1GNPATSLC6A5FNTAFNTB | |
| SCHEMBL2577664 | 0.88 | FOLH1 (0.44) | NOD1GNPATSLC6A5FNTAFNTB | |
| SCHEMBL2577881 | 0.87 | FOLH1 (0.50) | EPHX2NOD1GNPATFOLH1 | |
| SCHEMBL2577879 | 0.87 | FOLH1 (0.50) | EPHX2NOD1GNPATFOLH1 | |
| SCHEMBL2581221 | 0.87 | FOLH1 (0.45) | NOD1GNPATSLC6A5FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152288-A1 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF | SENJU PHARMACEUTICAL CO. LTD. (JP) | 2010-06-17 | — | — | US | claimed |
| EP-1371640-B1 | NOVEL A-LIPOIC ACID DERIVATIVE AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | claimed |
| EP-1371640-B1 | NOVEL A-LIPOIC ACID DERIVATIVE AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152288-A1 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF | TYR, SERPINB1, LPO | EPHX2 1159/4885CA2 931/4885CA4 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.